Genomma Lab: 2Q26 – Weak Results Streak Remains - Another EPS Miss On Contracting Top Line

研报英文原文证据摘录

Genomma Lab: 2Q26 – Weak Results Streak Remains - Another EPS Miss On Contracting Top Line

Joseph Giordano AC Latin America Equity Research

(55-11) 4950-3020 22 July 2026 J P M O R G A N

joseph.giordano@jpmorgan.com

opinions, forecasts or projections, which represent only one possible outcome. Furthermore, such opinions, forecasts or projections are subject

to certain risks, uncertainties and assumptions that have not been verified, and future actual results or events could differ materially. The value

of, or income from, any investments referred to in this material may fluctuate and/or be affected by changes in exchange rates. All pricing is

indicative as of the close of market for the securities discussed, unless otherwise stated. Past performance is not indicative of future results.

Accordingly, investors may receive back less than originally invested. This material is not intended as an offer or solicitation for the purchase or

sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives,

or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. This material

may include views on structured securities, options, futures and other derivatives. These are complex instruments, may involve a high degree of

risk and may be appropriate investments only for sophisticated investors who are capable of understanding and assuming the risks involved. The

recipients of this material must make their own independent decisions regarding any securities or financial instruments mentioned herein and

should seek advice from such independent financial, legal, tax or other adviser as they deem necessary. J.P.